The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The potential of circulating microRNA (miRNA) levels as a biomarker in drug development: An analysis of tumor-serum samples from patients on a phase I trial of saracatinib-paclitaxel (P)-carboplatin (C).
D. S. Tan
No relevant relationships to disclose
S. Aamdal
No relevant relationships to disclose
G. Freyer
No relevant relationships to disclose
R. J. Jones
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Other Remuneration - AstraZeneca
S. B. Kaye
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca
E. Pujade-Lauraine
No relevant relationships to disclose
J. Fog
No relevant relationships to disclose
M. Wrang Teilum
No relevant relationships to disclose
C. Glue
No relevant relationships to disclose
A. Baker
No relevant relationships to disclose
U. A. Emeribe
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
P. Elvin
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
C. Stephens
Employment or Leadership Position - AstraZeneca
M. Stuart
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
J. Walker
Employment or Leadership Position - AstraZeneca
E. Boven
Research Funding - Roche